Insider Selling: LivaNova (NASDAQ:LIVN) Director Sells $131,538.00 in Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,650 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $79.72, for a total transaction of $131,538.00. Following the sale, the director owned 7,934 shares in the company, valued at approximately $632,498.48. The trade was a 17.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

LivaNova Price Performance

Shares of LIVN traded up $2.24 during mid-day trading on Wednesday, reaching $82.40. The stock had a trading volume of 769,445 shares, compared to its average volume of 760,159. The firm has a market cap of $4.54 billion, a price-to-earnings ratio of 24.38 and a beta of 0.86. LivaNova PLC has a 12 month low of $48.82 and a 12 month high of $85.76. The business has a fifty day moving average of $80.67 and a 200 day moving average of $72.59. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. The firm had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.05 earnings per share. Equities analysts predict that LivaNova PLC will post 3.77 EPS for the current year.

Institutional Trading of LivaNova

Several hedge funds have recently bought and sold shares of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of LivaNova during the second quarter valued at about $4,053,000. California State Teachers Retirement System lifted its position in shares of LivaNova by 7,996.3% in the second quarter. California State Teachers Retirement System now owns 5,154,505 shares of the company’s stock worth $423,855,000 after buying an additional 5,090,840 shares in the last quarter. Turner Financial Group Inc. purchased a new stake in shares of LivaNova in the second quarter worth about $392,000. Public Employees Retirement System of Ohio bought a new position in LivaNova during the second quarter valued at approximately $37,000. Finally, GAMMA Investing LLC boosted its stake in LivaNova by 18.2% during the second quarter. GAMMA Investing LLC now owns 1,838 shares of the company’s stock valued at $151,000 after buying an additional 283 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on LIVN. Mizuho raised their price target on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Stifel Nicolaus set a $85.00 price objective on LivaNova in a research note on Wednesday, August 5th. Zacks Research cut LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Weiss Ratings raised LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, August 18th. Finally, Needham & Company LLC boosted their price target on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, LivaNova presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.12.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.